Inhibition of Ras prenylation: A novel approach to cancer chemotherapy

Saïd M. Sebti, Andrew Hamilton

Research output: Contribution to journalArticle

Abstract

The demonstration that Ras requires prenylation for its cancer-causing activity led several groups of investigators to an intense search for farnesyltransferase and geranylgeranyltransferase inhibitors as potential anticancer drugs. Rational design of small organic molecules that mimic the carboxyl terminal tetrapeptide prenylation site on Ras resulted in pharmacological agents capable of inhibiting Ras processing and selectively antagonizing oncogenic signaling, and suppressing human tumor growth in mouse models without side effects. These agents presently are undergoing advanced preclinical studies. This review describes the efforts of several groups to design, synthesize and evaluate the biological activities of several classes of prenyltransferase inhibitors. Several important issues, such as mechanism of action of prenyltransferase inhibitors and potential mechanisms of resistance to inhibition of K-Ras farnesylation, are also discussed.

Original languageEnglish (US)
Pages (from-to)103-114
Number of pages12
JournalPharmacology and Therapeutics
Volume74
Issue number1
DOIs
StatePublished - 1997

Fingerprint

Prenylation
Dimethylallyltranstransferase
Drug Therapy
Farnesyltranstransferase
Neoplasms
Research Personnel
Pharmacology
Growth
Pharmaceutical Preparations

Keywords

  • CAAX peptidomimetics
  • Cancer chemotherapy
  • Drug design
  • Farnesyltransferase
  • Geranylgeranyltransferase
  • Ras

ASJC Scopus subject areas

  • Pharmacology

Cite this

Inhibition of Ras prenylation : A novel approach to cancer chemotherapy. / Sebti, Saïd M.; Hamilton, Andrew.

In: Pharmacology and Therapeutics, Vol. 74, No. 1, 1997, p. 103-114.

Research output: Contribution to journalArticle

@article{8d0aa410529e4c53bcc7ed28bb581011,
title = "Inhibition of Ras prenylation: A novel approach to cancer chemotherapy",
abstract = "The demonstration that Ras requires prenylation for its cancer-causing activity led several groups of investigators to an intense search for farnesyltransferase and geranylgeranyltransferase inhibitors as potential anticancer drugs. Rational design of small organic molecules that mimic the carboxyl terminal tetrapeptide prenylation site on Ras resulted in pharmacological agents capable of inhibiting Ras processing and selectively antagonizing oncogenic signaling, and suppressing human tumor growth in mouse models without side effects. These agents presently are undergoing advanced preclinical studies. This review describes the efforts of several groups to design, synthesize and evaluate the biological activities of several classes of prenyltransferase inhibitors. Several important issues, such as mechanism of action of prenyltransferase inhibitors and potential mechanisms of resistance to inhibition of K-Ras farnesylation, are also discussed.",
keywords = "CAAX peptidomimetics, Cancer chemotherapy, Drug design, Farnesyltransferase, Geranylgeranyltransferase, Ras",
author = "Sebti, {Sa{\"i}d M.} and Andrew Hamilton",
year = "1997",
doi = "10.1016/S0163-7258(97)00014-4",
language = "English (US)",
volume = "74",
pages = "103--114",
journal = "Pharmacology and Therapeutics",
issn = "0163-7258",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Inhibition of Ras prenylation

T2 - A novel approach to cancer chemotherapy

AU - Sebti, Saïd M.

AU - Hamilton, Andrew

PY - 1997

Y1 - 1997

N2 - The demonstration that Ras requires prenylation for its cancer-causing activity led several groups of investigators to an intense search for farnesyltransferase and geranylgeranyltransferase inhibitors as potential anticancer drugs. Rational design of small organic molecules that mimic the carboxyl terminal tetrapeptide prenylation site on Ras resulted in pharmacological agents capable of inhibiting Ras processing and selectively antagonizing oncogenic signaling, and suppressing human tumor growth in mouse models without side effects. These agents presently are undergoing advanced preclinical studies. This review describes the efforts of several groups to design, synthesize and evaluate the biological activities of several classes of prenyltransferase inhibitors. Several important issues, such as mechanism of action of prenyltransferase inhibitors and potential mechanisms of resistance to inhibition of K-Ras farnesylation, are also discussed.

AB - The demonstration that Ras requires prenylation for its cancer-causing activity led several groups of investigators to an intense search for farnesyltransferase and geranylgeranyltransferase inhibitors as potential anticancer drugs. Rational design of small organic molecules that mimic the carboxyl terminal tetrapeptide prenylation site on Ras resulted in pharmacological agents capable of inhibiting Ras processing and selectively antagonizing oncogenic signaling, and suppressing human tumor growth in mouse models without side effects. These agents presently are undergoing advanced preclinical studies. This review describes the efforts of several groups to design, synthesize and evaluate the biological activities of several classes of prenyltransferase inhibitors. Several important issues, such as mechanism of action of prenyltransferase inhibitors and potential mechanisms of resistance to inhibition of K-Ras farnesylation, are also discussed.

KW - CAAX peptidomimetics

KW - Cancer chemotherapy

KW - Drug design

KW - Farnesyltransferase

KW - Geranylgeranyltransferase

KW - Ras

UR - http://www.scopus.com/inward/record.url?scp=0030749464&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030749464&partnerID=8YFLogxK

U2 - 10.1016/S0163-7258(97)00014-4

DO - 10.1016/S0163-7258(97)00014-4

M3 - Article

C2 - 9336018

AN - SCOPUS:0030749464

VL - 74

SP - 103

EP - 114

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

SN - 0163-7258

IS - 1

ER -